Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Journey Medical CorporationNASDAQ: DERM

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$1.49M, compared with -$3.32M a year earlier. Trailing-twelve-month operating income was -$6.34M.

Context

  • Operating income amounted to 13.2% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of -$1.2M (+85.3%) for the fiscal year ending Dec 2026, a step up from the +40.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.49M-236.8% QoQ
Last fiscal yearDec 2025
-$8.17M+40.3% YoY
LTMMar 2026
-$6.34M+8.3% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.1%+109.5%+54.4 pp
1 year+40.3%+85.3%+45.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(8.17M) USD
Year-over-year change
+40.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.3% is the 4th highest of 10, against a peer median of -30.1%.
  • Operating income amounts to 9.8% of revenue for DERM, versus a peer median of 193.6%.
DERM Competitors
Operating Income for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$5.63M USD+53.2%—11.0%
DERMJourney Medical CorporationLTM Mar 2026-$6.34M USD+8.3%—9.8%
OGIOrganigram Global Inc.LTM Mar 2026-CA$14.13M CAD+26.2%—5.2%
HSDTSolana CompanyLTM Mar 2026-$18.86M USD-30.1%—196.6%
MDWDMediWound Ltd.LTM Mar 2026-$28.03M USD-34.3%—193.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$54.96M USD+20.1%—168.0%
OSUROraSure Technologies, Inc.LTM Mar 2026-$73.04M USD-105.7%—64.6%
NYXHNyxoah S.A.LTM Mar 2026-€86.04M EUR-28.0%—527.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$91.32M USD-74.1%—5144.5%
IVAInventiva S.A.FY2025-€130.95M EUR-34.2%—2921.0%
Peer median (excluding DERM) —-30.1%—193.6%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.